News

Social media smartphone application–based interventions significantly improved adherence and parental knowledge among families of children with congenital ectopia lentis

ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there currently are no approved treatments.

A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025.

A survey collected demographic data, ocular and medical history, and responses assessing knowledge of glaucoma and cataracts in the Qassim region of Saudi Arabia.

Phase I/II safety and efficacy study currently enrolling.

In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

Alcon acquired the historic ophthalmic instrument company in 2000

As part of its five-year strategic plan, Prevent Blindness has promoted five individuals to further the organization’s mission.

Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and outlines his priorities for the year ahead as incoming ASCRS president.

Congenital ectopia lentis is a rare ocular disease characterized by the dislocation or displacement of the lens.

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting

Eyecyte-RPE is a suspension of human induced pluripotent stem cells derived from retinal pigment epithelial cells.

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts.

Eyecyte-RPE is a suspension of human induced pluripotent stem cell–derived retinal pigment epithelial cells.

Congenital ectopia lentis is a rare ocular disease characterized by the dislocation or displacement of the lens.

Nau will lead the company in a new phase of growth and innovation.

In their study, 16 ophthalmologists, including attending physicians and residents with levels of experience ranging from 1 to 9 years, were included.

The partnership will integrate Ocuco’s optical software solution, Acuitas 3, with Nextech’s Ophthalmic Platform.

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).

A new study found that an artificial intelligence reading label system improves ophthalmologists' diagnostic accuracy for retinal diseases and could be valuable in future medical education.

VX01-DR-201, is a phase 2, multicenter, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).

The company's therapeutic candidates include a bispecific antibody to target vascular retinal diseases

Researchers introduce a multistage dual-branch network to improve accuracy and efficiency.

PYK-2101 is a focal hydrogel retinal sealant for use in patients undergoing surgery for a detached retina.